Inhaled drug shows promise for rare lung disease combination

A therapeutic rule rooted successful decades of pulmonary vascular probe is entering a caller signifier of objective development. The investigational inhaled cause mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced marked and accordant effects successful a randomized signifier 2 survey involving patients with pulmonary hypertension associated with interstitial lung illness (PH-ILD), 1 of the astir challenging forms of pulmonary vascular disease.